Multi-study Integration of Brain Cancer Transcriptomes Reveals Organ-Level Molecular Signatures

TL;DR

This study develops a new method to identify molecular signatures for brain cancers using integrated transcriptomic data from multiple studies, achieving high prediction accuracy and addressing data heterogeneity.

Contribution

A novel approach for integrating multi-study transcriptomic data to derive robust brain cancer signatures with improved reproducibility and predictive performance.

Findings

Developed a 44-gene brain cancer marker panel.

Achieved 90% accuracy in phenotype prediction.

Meta-signatures improve robustness across datasets.

Abstract

We utilized abundant transcriptomic data for the primary classes of brain cancers to study the feasibility of separating all of these diseases simultaneously based on molecular data alone. These signatures were based on a new method reported herein that resulted in a brain cancer marker panel of 44 unique genes. Many of these genes have established relevance to the brain cancers examined, with others having known roles in cancer biology. Analyses on large-scale data from multiple sources must deal with significant challenges associated with heterogeneity between different published studies, for it was observed that the variation among individual studies often had a larger effect on the transcriptome than did phenotype differences, as is typical. We found that learning signatures across multiple datasets greatly enhanced reproducibility and accuracy in predictive performance on truly independent validation sets, even when keeping the size of the training set the same. This was most likely due to the meta-signature encompassing more of the heterogeneity across different sources and conditions, while amplifying signal from the repeated global characteristics of the phenotype. When molecular signatures of brain cancers were constructed from all currently available microarray data, 90 percent phenotype prediction accuracy, or the accuracy of identifying a particular brain cancer from the background of all phenotypes, was found. Looking forward, we discuss our approach in the context of the eventual development of organ-specific molecular signatures from peripheral fluids such as the blood.